Page URL:

Test for breast cancer risk criticised

20 October 2008
Appeared in BioNews 480

Icelandic biotech company, DeCODE Genetics, last week launched a controversial genetic test to assess a woman's risk of the most common forms of breast cancer. The 1,625 dollar test, which has attracted criticism, comes at a time when new standards of best practice are being drawn up in the UK to try and control the boom of unregulated genetic tests now being marketed to the public.

95 per cent of breast cancer cases are non-hereditary or 'sporadic', meaning they result from multiple, interacting, environmental and genetic factors. Nevertheless, some common genetic variations have been identified that, although not solely responsible for causing specific cancers, are linked to a slightly increased lifetime risk of developing the disease.

The new test looks at seven such gene variants, known as SNPs, to help estimate a woman's lifetime risk of developing breast cancer relative to the general population. According to the American Cancer Society, the average lifetime risk for women of European descent is 12 percent and test scores could range from 4.0 times average lifetime risk to less than 0.4 times.Dr Kari Stefansson, chief executive of DeCODE, told the Washington Post: 'What this does for women is allow them to assess their personal risk for the common forms of breast cancer. That's what you need to do to make early diagnoses or take preventive measures'.

However, other scientists have argued that the test has little clinical value.

Professor Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology said, 'There is at least a significant chance this test could falsely reassure some women and alarm others.'

Professor Mary-Claire King, a geneticist and breast cancer expert at the University of Washington, and others have questioned whether the markers used in the test have been properly scientifically validated. 'It's meaningless, and it could very easily introduce real confusion,' she said of the test. 'The idea of introducing into medical practice a test whose predictive value is completely unvetted biologically is frightening,' she added.

Furthermore, there is also widespread concern that, in the absence of professional medical advice and counselling, members of the public may misinterpret the test, which is available over the internet.

It remains unclear how accurate the test, which has been researched using women of European descent, would be for women of other backgrounds, although the company is taking steps to assess this, said Dr Stefansson.

Breast cancer tests - not worth the price?
MSNBC |  8 October 2008
DeCODE Launches DeCODE BreastCancer(TM), A Genetic Test To Screen For Risk Of The Common Forms Of Breast Cancer
Medical News Today |  9 October 2008
Firm Says Test Judges Risk For Common Breast Cancers
The Washington Post |  8 October 2008
Test for breast cancer susceptibility launched
phg foundation |  13 October 2008
6 June 2011 - by Dr Rachael Panizzo 
Scientists have identified a set of 15 genes that are associated with triple-negative breast cancer (TNBC), an aggressive form of the disease that does not respond to the drugs commonly used to treat other types of breast cancer...
13 October 2008 - by Ailsa Stevens 
In response to widespread criticism over the value of genetics tests aimed at predicting disease susceptibility, the Silicon Valley based biotech company 'Navigenetics Inc.' has teamed up with 'Scripps Translational Science Institute', an organisation which facilitates the translation of discoveries from the lab into the clinic. Advances...
15 September 2008 - by Ailsa Stevens 
BioNews reporting from the British Society for Human Genetics (BSHG) annual conference in York:By Ailsa Taylor:New standards of best practice will be drawn up in the UK to try and control the boom of unregulated genetic tests now being marketed to the public via the internet, says Christine...
10 March 2008 - by Katy Sinclair 
By Katy Sinclair: The recent explosion of genetic tests being marketed to consumers has led to calls for the market to be regulated, and for the clinical utility of the tests available to be validated. The increase in genome association studies has led to the discovery of genetic markers for...
10 December 2007 - by Ailsa Stevens 
A new report - 'More Genes Direct' - published by the UK's Human Genetics Commission (HGC) called for tighter regulation and a review of the European Law which deals with genetic tests. The report - an update of the 2003 version - aims to address growing concerns over the number of...
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.